Previous Article |
Table of Contents
| Next Article
Howard Hughes Medical Institute, Department of Molecular Biology,
Princeton University, Princeton, NJ 08544-1014
Contributed by Thomas Shenk, December 31, 1996
Some epidemiological studies have suggested a possible link between
human cytomegalovirus (HCMV) infection and various malignancies, and
HCMV has been shown to transform cultured cells. However, viral DNA is
not detected in most transformants, and the mechanism by which HCMV
might contribute to oncogenesis has remained obscure. Here we show that
the HCMV immediate early 1 and 2 genes
can cooperate with the adenovirus E1A gene to generate
transformed foci of primary baby rat kidney cells. HCMV gene expression
is transient and viral DNA is not present in clonal cell lines derived
from the transformed foci. We find that the HCMV immediate early
proteins are mutagenic, and we propose that HCMV has the potential to
contribute to oncogenesis through a "hit-and-run" mechanism, by
inducing mutations in cellular genes.
Serological and molecular studies have suggested a possible
association of human cytomegalovirus (HCMV) with the development of
human malignancies, including cervical carcinoma, colon carcinoma, and
prostate cancer (reviewed in refs. 1-5). A variety of laboratory observations demonstrate that HCMV has oncogenic potential, supporting the idea that HCMV might contribute to the induction of human tumors.
HCMV has been shown to induce cervical neoplasia in mice (6), it can
morphologically transform human (7, 8) as well as other mammalian
(9-11) cells in culture, and HCMV-transformed cells can form tumors in
experimental animals (6, 8). In vitro assays have identified
three regions on the HCMV genome with transforming activity (reviewed
in ref. 5). However, if HCMV infection does contribute to tumor
induction in humans, the mechanism underlying HCMV-induced oncogenesis
is very likely different from that of DNA viruses that are known to
play a role in human malignancies. Whereas specific viral genes are
present and expressed in tumors induced by agents such as Epstein-Barr
virus and the human papillomaviruses, no specific HCMV DNA sequence
element is reliably present and often no viral DNA can be detected in cells transformed by HCMV (reviewed in refs. 4 and 12).
We have previously reported (13) that the two most abundantly expressed
immediate-early gene products of HCMV, IE1 and IE2 (reviewed in ref.
14), inhibit the induction of apoptosis by tumor necrosis
factor The mammalian expression plasmids pCMV-E1A (17),
pCMV-19-kDa (18); pCGN-IE1 (IE1) and pCGN-IE2 (IE2) (13) and their parental vector pCGN (19) have all been described previously. pPuro- BRK cells, which have been used
extensively to assay the transforming activity of adenovirus oncogenes
(21, 22), were used to test the oncogenic potential of the HCMV
immediate early genes. Kidneys from 6-day-old Fisher rats were treated
with 0.125% trypsin to produce a uniform cell suspension. These cells
were incubated in Dulbecco's modified Eagle's medium (DMEM)
containing 10% fetal calf serum (FCS) for 4 days, then trypsinized and
frozen in aliquots in 90% FCS plus 10% dimethyl sulfoxide. One day
before transfection, aliquots of cells were thawed and counted, and
1.6 × 106 viable cells were seeded per 100-mm dish
into medium containing 10% FCS. Transfection was by the calcium
phosphate precipitation method (23), with 5 µg per dish of each of
the expression plasmids. Parental vectors were used to equalize the
amount of plasmid DNA among different transfections, and the total
amount of DNA was adjusted to 30 µg per dish with salmon sperm DNA.
After 16 hr, DNA precipitates were removed, and cells were allowed to
recover in medium containing 10% FCS for 24 hr. Finally, cells from
each dish were split into three 60-mm dishes and incubated in medium containing 5% FCS until foci appeared. Some foci were cloned and maintained in DMEM containing 10% FCS. Others were visualized with 4%
Giemsa stain.
Immunoprecipitation of IE1 and IE2
proteins from 35S-labeled cell extracts was as described
(16) with monoclonal antibody mAB810 (Chemicon), which interacts with
the common amino-terminal domain shared by the two immediate early
proteins. Expression of E1A was assayed by immunoprecipitation from
unlabeled cell extracts by using the E1A-specific monoclonal antibody
M73 (24). The immune complexes were resolved by electrophoresis on
SDS/8% polyacrylamide gels, transferred to nitrocellulose, subjected to immunoblot analysis with antibody M73, and visualized by using ECL
reagents (Amersham).
For analysis of protein expression by immunofluorescence, BRK cells
seeded on coverslips were transfected by the calcium phosphate precipitation method (23) either with pCMV-E1A plus pCMV-19-kDa or with
pCMV-E1A plus pCGN-IE1 and pCGN-IE2. At appropriate times after
transfection, two coverslips were removed from each transfected culture, cells were fixed in phosphate-buffered saline containing 4%
paraformaldehyde, and the preparations were stored in
phosphate-buffered saline at 4°C. After coverslips were collected at
all time points, the cells on them were allowed to react with the
appropriate primary antibodies. For the two sets of coverslips
collected from cells transfected with vectors expressing the E1A plus
E1B-19-kDa proteins, one set was stained with anti-E1A antibody (M73),
and the other was stained with monoclonal antibody to E1B-19-kDa
(Oncogene Science). Coverslips with cells transfected with vectors
expressing E1A, IE1, and IE2 proteins were allowed to react with either
anti-E1A (M73) or anti-HCMV IE1/2 (mAB810) antibody. The samples were
then stained with fluorescein isothiocyanate (FITC)-conjugated
secondary antibodies and visualized with a confocal microscope (Bio-Rad model MRC600). Each image is from an independent coverslip.
Total cellular DNA was prepared from
1.5 × 107 cells of each cell line by using DNAzol
(BRL). A 15-µg sample of each DNA was digested with EcoRI
and BamHI (10 units/µg of DNA) for 12 hr and was
resolved by electrophoresis on a 0.7% agarose gel. Southern blotting
and hybridization were performed as described (16). The entire IE1 and
IE2 cDNAs were used as templates to make probe by random-primed DNA
synthesis.
The D422 CHO cell line (25) was a generous
gift from L. A. Chasin (Columbia University). The cells were maintained
in medium ( To assay for mutations in p53, immunoprecipitations were performed from
35S-labeled cell extracts as described (16), using
monoclonal antibody pAb240, which specifically recognizes mutant p53.
For DNA sequencing, the DNA-binding domain of p53 (amino acids
113-301) was obtained from selected BRK cell lines by reverse
transcription followed by PCR amplification using the Pfu
DNA polymerase (Stratagene). Two independent reverse
transcription/PCRs were performed for each cell line. Amplified
products were inserted in PCR-Script cloning vector (Stratagene) and
sequenced.
To
evaluate the possibility that the HCMV IE1 and
IE2 genes might have transforming potential, we transfected
primary BRK cells with plasmids encoding the IE1 and IE2 proteins as
well as the adenovirus E1A protein. IE1 or IE2 alone enhanced the
focus-forming activity of E1A by a factor of 2-3 (Fig.
1A); while IE1 and IE2 together
increased the transforming activity of E1A by a factor of about 8, a
level comparable to the activity of E1A plus the adenovirus E1B protein
(Fig. 1 A and B) or Bcl-2 (15). As reported previously (15), it was extremely difficult to clone the flat foci
induced by E1A alone. Of the 17 E1A-induced foci that were tested, only
one was recovered as a stable cell line (6%). In contrast, much higher
cloning efficiencies were obtained for the multilayered foci induced by
E1A plus E1B (9/12, 75%) or E1A plus IE1 and IE2 (12/18, 67%).
These results clearly demonstrate that the IE1 and IE2 genes have
transforming potential, and they show that there is cooperation between
the two immediate early genes. In the absence of E1A, IE1 and IE2 did
not produce any foci, nor did they complement activated Ras to
transform BRK cells (Fig. 1A).
The morphological transforming regions of herpes simplex viruses do not
specify any identifiable polypeptide products, and it was hypothesized
that the DNA sequence itself is responsible for HSV-2-induced
transformation (reviewed in refs. 12, 26, and 27). To determine whether
this is also the case in our system, we reversed the direction of the
IE1 and IE2 cDNAs in the expression vectors so that they resided in an
antisense orientation relative to the promoter. These antisense
plasmids failed to cooperate with E1A to transform BRK cells (Fig.
1C), suggesting that the IE1 and IE2 gene products are
required for transformation.
To
gain insight to the mechanism by which IE1 and IE2 contribute to
oncogenicity, we examined the expression of the transfected genes in a
series of transformed BRK cell lines. In cell lines derived by
transfection with E1A plus E1B, both E1A (Fig.
2C) and E1B (data not shown) proteins
are readily detected in all cell lines tested. Unexpectedly, however,
IE1 or IE2 protein was not detected in any of the
E1A/IE1/IE2-derived cell lines, either by immunoblot analysis (not
shown) or by immunoprecipitation of 35S-labeled cell
extracts (Fig. 2A). IE1 and IE2 DNA sequences were completely absent from these cell lines, as judged by Southern blot
analysis (Fig. 2B) or PCR amplification of DNA
sequences located within the cDNAs (data not shown). Furthermore, E1A
protein expression was detected only in a subset of such cell lines
(Fig. 2C).
A time course experiment was performed to examine the expression of the
transforming proteins after cotransfection into BRK cells. As shown in
Fig. 3, the IE1 and IE2 proteins initially accumulated to high levels as judged by immunofluorescence, but their
expression tapered off rapidly. By day 5 after transfection, virtually
no IE1 or IE2 protein was detected by immunofluorescent staining, even
in cells that had begun to form foci. The faint fluorescence evident in
cells assayed for IE1 and IE2 expression on days 5, 13, and 19 is a
nonspecific background signal. In contrast, the E1B protein was
detected in cells transformed by the E1A plus E1B proteins throughout
the entire 27-day time course, and the E1A protein was detected
throughout the time course in cells transformed by E1A/IE1/IE2 or
by E1A/E1B. Even though the IE1 and IE2 proteins disappeared rapidly,
their transforming activity was evident: a similar number of foci
formed whether the cells were transfected with E1A/E1B or with
E1A/IE1/IE2 in the time course experiment (data not shown).
These results are
difficult to fit into the conventional theory of viral oncogenesis,
where the continuous expression of an oncogene is generally required to
sustain a transformed phenotype. Rather, they are consistent with a
"hit-and-run" model (reviewed in ref. 27) in which the HCMV genes
act transiently to induce a transformed state. Several earlier reports
indicating that HCMV infection results in cellular chromosome damage
(28-31) prompted us to ask whether IE1 and IE2 might cause a
"hit" by inducing mutations in cellular genes. To test this
possibility, we examined whether the IE1 and IE2 proteins could alter
the mutation rates of aprt and hprt, two cellular
genes that are often used as indicators of mutation frequency. A
CHO-derived cell line, D422, which is hemizygous for both
aprt and hprt loci, was chosen as the indicator cell (25). As shown in Fig. 4, when IE1 and IE2
expression plasmids were introduced into D422, the frequency of
mutations at the aprt and hprt loci increased by
a factor of 4 to 10 over the background level, whereas transfection
with the expression plasmid for E1A or the vector with no insert did
not significantly change the mutation frequency. These results
demonstrate that IE1 and IE2 have the capacity to induce mutations. In
fact, considering that about 10% of the cells were transfected (data
not shown), the actual mutation frequencies induced by the IE1 and IE2
proteins appear to be comparable to that induced by EMS, a chemical
mutagen used in the experiments as a positive control (Fig. 4).
Since mutant p53 alleles are known to cooperate with the adenovirus E1A
protein to transform rodent cells (32), we tested whether the
p53 gene was altered in the E1A/IE1/IE2 transformants. Immunoprecipitation with an antibody (pAb240) that recognizes some
mutant p53 alleles but not wild-type p53 revealed that at least 6 of 10 transformed cell lines contained mutant p53 (Fig. 5A). The p53 DNA-binding domain was
amplified and sequenced in three of the transformants, and each was
found to contain a missense mutation (Fig. 5B). It seems
likely that the p53 mutations result from the temporary expression of
the IE1 and IE2 gene products, since mutant p53 alleles arise only
rarely in BRK cells receiving the E1A gene alone (33). As a
result, the presence of mutant p53 alleles is consistent with a
mutagenesis-based "hit-and-run" model for transformation.
Further, since mutant p53 alone does not transform BRK cells (32), we
anticipate that the cells lacking E1A protein (Fig. 2C)
contain additional lesions in cellular genes that contribute to the
transformed phenotype.
The two most abundant immediate-early products of HCMV, IE1 and
IE2, can cooperate with the E1A oncoprotein to transform primary BRK
cells (Fig. 1). The IE1 and IE2 products are present only transiently
during the transformation process (Figs. 2 and 3), and they promote the
accumulation of mutations (Figs. 4 and 5). The HCMV genes are lost
after mutations arise that promote cell growth, presumably because
continued mutagenesis would be deleterious to cell survival. Thus, the
IE1 and IE2 proteins cooperate with E1A to sponsor "hit-and-run"
transformation.
Earlier reports have documented the transforming potential of both
herpes simplex virus and HCMV DNAs and have demonstrated that viral DNA
is often not retained in transformed cells and tumor samples (4, 12,
26, 27, 34-38). Further, several studies have indicated that infection
with herpesviruses or transfection with viral DNA induces mutations in
cellular genes (12, 39-45). It has been hypothesized (12, 26) that
herpesvirus DNAs might cause mutations by movement of insertion
sequence-like elements present in the viral genomes. Our results
demonstrate that the HCMV IE1 and IE2 coding regions do not have
transforming potential when they are positioned in an antisense
orientation relative to the promoter (Fig. 1C); transient
expression of the immediate early gene products is required for
transformation. As yet, we can only speculate on the mechanism by which
the IE1 and IE2 products induce the accumulation of mutations. They
might increase the error frequency of cellular DNA polymerases or
interfere with cellular DNA repair processes. The latter possibility is
intriguing because defects in mismatch repair genes play a role in some
common human cancers (reviewed in ref. 46).
The finding that many of the transformed BRK cell lines contain mutated
p53 alleles suggests that mutation of p53 might be one of the
mechanisms by which IE1 and IE2 contribute to transformation. In a
similar vein, Boldogh et al. (47) have shown that three different cell lines transformed by HCMV infection harbor an activating mutation in both alleles in H-Ras. However, in both of these cases it
is unclear whether the mutations in H-Ras or p53 are a direct result of
the mutagenic activity of HCMV gene products. The mutations could arise
as the transformants are selected for growth in culture.
Given the mutagenic activity of IE1 and IE2, it is puzzling why they do
not transform primary cells in the absence of E1A (Fig.
1A). A plausible explanation for this observation is
that mutagenesis by IE1 and IE2 might require active DNA replication, which rarely happens in primary BRK cells unless E1A is present to
stimulate DNA replication and cell cycle progression (48). In the
established D422 cells used to assay mutation frequencies, however,
active cell division might bypass the need for E1A.
Could the mutagenic activity of IE1 and IE2 contribute to cancer in
humans? Cell cycle progression is inhibited in productively infected
cells (49-52), and most infected cells are eventually killed as HCMV
completes its replication cycle. However, defective virus particles
arising spontaneously in an infected individual could infect cells in
the absence of wild-type virus, and they could express a subset of the
viral genes, including IE1 and IE2. Alternatively, the wild-type virus
might express only subsets of its genes in certain cell types, as has
been suggested for the interaction of HCMV with peripheral blood
mononuclear cells (53, 54). Nonproductive infections could induce the
accumulation of mutations in cellular growth regulatory genes, which
ultimately leads to cell transformation. The induction of cervical
neoplasia in mice by HCMV (4) is likely an example of an oncogenic
event resulting from an abortive infection, because HCMV expresses a limited number of its genes in rodent cells (55, 56). If cell growth is
induced by a nonproductive infection, then, as indicated above, the
continued presence of mutagenic viral gene products would likely be
detrimental. This would select for malignant cells that have lost the
viral genome, and, as a result, it would be very difficult to implicate
the widespread pathogen in tumor induction.
Proc. Natl. Acad. Sci. USA
Vol. 94,
pp. 3341-3345,
April 1997
Microbiology
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
ABBREVIATIONS
REFERENCES
(TNF-
) or the adenovirus E1A oncoproteins. The fact that
the IE1 and IE2 gene products are able to inhibit apoptosis
raised the interesting possibility that they might cooperate with the
adenovirus E1A oncoproteins to transform primary rodent cells, as do
the adenovirus E1B 19-kDa (E1B) protein and the cellular Bcl-2 protein,
each of which can block apoptosis (15, 16). In this report, we
show that the IE1 and IE2 gene products can, indeed, cooperate with E1A
to transform primary baby rat kidney (BRK) cells. Unexpectedly,
however, we find that expression of the IE1 and IE2 proteins is
transient; HCMV proteins and DNA are not present in transformed cell
lines derived from the foci. The IE1 and IE2 gene products are
mutagenic, and we propose that they contribute to transformation at
least in part by a mutagenesis-based "hit-and-run" mechanism.
Plasmids.
IE1 and pPuro-
IE2 contain IE1 and IE2 cDNAs, respectively, in an antisense orientation in the pBabe-puro expression vector (20).
-MEM) containing 10% FCS. Subconfluent cultures of D422
were transfected by the calcium phosphate precipitation technique (23) with 5 µg of each expression plasmid per 100-mm dish. The total amount of DNA was adjusted to 30 µg per dish with parental vector and
salmon sperm DNA. After transfection, cells were incubated in
nonselective growth medium for 4 days. Mutation frequencies were
determined by plating 2 × 105 treated cells into each
100-mm dish in medium containing 10% dialyzed FCS supplemented with
either 200 µM 2,6-diaminopurine (selection for aprt
mutants) or 20 µM 6-thioguanine (selection for hprt
mutants). Drug-resistant colonies usually appeared within 7-8 days,
and they were stained with 4% Giemsa solution. For each culture, 200 cells were also plated in nonselective medium to determine plating
efficiency. As a control, D422 cells were treated with 0.2 mg/ml
ethyl methanesulfonate (EMS) for 18 hr and then incubated in
nonselective medium for 8 days before selection for drug-resistant
colonies.
HCMV IE1 and IE2 Can Cooperate with E1A for Transformation.
Fig. 1.
The HCMV IE1 and IE2 genes cooperate with the
adenovirus E1A gene to transform primary BRK cells.
(A) Representative BRK transformation assay showing the
number of foci that arise in response to transfection with different
combinations of expression plasmids. (B) BRK transformation assays demonstrating that IE1 plus IE2 cooperate with E1A for transformation. The number of foci reported is the total from 10 plates
assayed in four independent experiments. (C) Representative experiment showing that IE1 and IE2 cDNAs cloned in an antisense orientation (
IE1 and
IE2) have no transforming activity. The number of foci reported is the total from three 100-mm plates. In all
experiments, the gene products expressed by transfected plasmids are
listed below the bars. Cultures transfected with pCGN containing no
insert are designated vector.
[View Larger Version of this Image (37K GIF file)]
Fig. 2.
HCMV IE1 and IE2
genes and their products are not present in transformed BRK cell lines.
(A) Lack of expression of the IE1 or IE2 protein in
transformed BRK cell lines when assayed by immunoprecipitation of
35S-labeled cell extracts using monoclonal antibody mAB810.
A-1 is a cell line established by transfection with the E1A-expressing plasmid alone. A/1/2-1 to A/1/2-10 are cell lines transformed by E1A plus IE1 and IE2. Lanes designated HCMV INF display
immunoprecipitates from HCMV-infected human foreskin fibroblasts; lane
13 is an exposure 1/8 as long as that presented for lanes 1-12.
Numbers to the left of the gel mark the positions of marker proteins
whose sizes are indicated in kDa. (B) Southern blot analysis
showing the lack of IE1- or IE2-specific
DNA in E1A/IE1/IE2-induced transformants (lanes 1-10). A/B-1 and
A/B-2 are cell lines transformed with E1A and E1B-19-kDa. HeLa, 293, and HP1.14 (a derivative HeLa cells expressing IE1) are included as
controls. pCGN-IE1 and pCGN-IE2 are IE1 and IE2 expression plasmids,
respectively, in amounts equivalent to the rest of the samples,
assuming they contain one copy of each of the HCMV genes per cell.
Numbers to the left of the gel are marker DNA sizes in kb.
(C) Expression of E1A protein as determined by
immunoprecipitation followed by immunoblot analysis, both with
monoclonal antibody M73 to E1A. Lanes are labeled as in
A and B. Numbers to the left of the gel
are marker protein sizes in kDa. Autoradiograms were scanned and
cropped using Photoshop and figures were prepared using Freehand
software.
[View Larger Version of this Image (63K GIF file)]
Fig. 3.
The IE1 and IE2 gene products are expressed
transiently during the transformation of BRK cells. BRK cells seeded on
coverslips were transfected with expression plasmids for E1A and
E1B-19-kDa (Left) or plasmids for E1A and IE1 and IE2
(Right). At 2, 5, 13, and 19 days after transfection,
two coverslips from each transfection were fixed and kept in
phosphate-buffered saline until coverslips for all time points were
collected. Expression of the transfected genes was examined by indirect
immunofluorescent staining with appropriate monoclonal antibodies.
Anti-E1A, anti-E1B-19-kDa, and anti-IE1/2 identify the antibodies
used for the immunofluorescent staining. Images are from independent
coverslips. The images from days 13 and 19 display transformed foci
whose cells were positive for E1A and E1B-19-kDa proteins, but
completely negative for IE1 and IE2 protein expression. (×50).
[View Larger Version of this Image (81K GIF file)]
Fig. 4.
The IE1 and IE2 gene products increase the
frequency of mutation within the aprt (A) and
hprt (B) genes. D422 cells were transfected with expression plasmids (identified below bars). After an incubation period of 4 days, aprt
/
and
hprt
/
mutants were selected by the addition of 200 µM diaminopurine or 20 µM 6-thioguanine, respectively, to otherwise
purine-free medium. The frequencies of mutation at the two loci for
cells exposed to 0.2 mg/ml EMS for 18 hr are also shown.
[View Larger Version of this Image (29K GIF file)]
Fig. 5.
BRK cells transformed by E1A, IE1, and IE2 often
contain mutant p53 alleles. (A) Immunoprecipitation of
35S-labeled cell extracts with a mutant p53-specific
antibody, pAb240. 10(1)val5@39°C indicates 10(1) cells harboring a
temperature-sensitive form of p53 cultured at 39°C. The left-most
lane displays marker proteins whose sizes in kDa are indicated to the
left of the autoradiogram. (B) Identification of missense
mutations in three E1A/IE1/IE2 transformants. Two independent PCR
amplifications of the central DNA-binding domain of p53 were performed
for each cell line, and two clones were isolated and sequenced from
each amplification reaction. The A/1/2-3 and A/1/2-10 cell
lines contain both mutant and wild-type p53 sequences, indicating that
only one allele is mutated within the DNA-binding domain. All clones
from A/1/2-8 contained a mutation, indicating that both alleles
might be altered in these cells.
[View Larger Version of this Image (44K GIF file)]
*
To whom reprint requests should be addressed.
We thank Dr. L. Chasin (Columbia University) for cell lines and helpful advice on mutagenesis assays, J. Goodhouse for assistance with confocal microscopy, and C. Patterson for extracts from HCMV-infected cells. This work was supported by a grant from the National Cancer Institute (CA41086). Y.S. and H.Z. were Postdoctoral Fellows of the New Jersey Commission on Cancer Research. T.S. is an American Cancer Society Professor and an Investigator of the Howard Hughes Medical Institute.
HCMV, human cytomegalovirus; BRK, baby rat kidney; FCS, fetal calf serum; EMS, ethyl methanesulfonate.
| 1. | Huang, E.-S., Boldogh, I. & Mar, E. C. (1983) in Viruses Associated with Human Cancer, ed. Fillips, L. (Dekker, NY), pp. 161-194. |
| 2. | Huang, E.-S., Mar, E.-C., Boldogh, I. & Baskar, J. (1984) Birth Defects 20, 193-211 . |
| 3. | Rapp, F. & Robbins, D. (1984) Birth Defects 20, 175-192 . |
| 4. |
Macnab, J. C. M.
(1987)
J. Gen. Virol.
68,
2525-2550
|
| 5. | Rosenthal, L. J. & Choudhury, S. (1993) in Molecular Aspects of Human Cytomegalovirus Disease, eds. Becker, Y. & Darai, G. (Springer, NY), pp. 412-436. |
| 6. |
Heggie, A. D., Wentz, W. B., Reagan, J. W. & Anthony, D. D.
(1986)
Cancer Res.
46,
5211-5214
|
| 7. |
Geder, L., Lausch, R., O'Neill, F. & Rapp, F.
(1976)
Science
192,
1134-1137
|
| 8. | Smiley, M. L., Mar, E.-C. & Huang, E.-S. (1988) J. Med. Virol. 25, 213-226 [ISI][Medline] . |
| 9. | Albrecht, T. & Rapp, F. (1973) Virology 55, 53-61 [CrossRef][ISI][Medline] . |
| 10. | Boldogh, I., Gonczol, E. & Vaczi, L. (1978) Acta Microbiol. Acad. Sci. Hung. 25, 269-275 [Medline] . |
| 11. | Yelle, J. & Hamelin, C. (1986) Cell Biol. Int. Rep. 10, 493-499 [Medline] . |
| 12. | Galloway, D. A., Buonaguro, F. M., Brandt, C. R. & McDougall, J. K. (1986) Cancer Cells 4, 355-361 . |
| 13. | Zhu, H., Shen, Y. & Shenk, T. (1995) J. Virol. 69, 7960-7970 [Abstract]. |
| 14. | Mocarski, E. S. (1996) in Fields Virology, eds. Fields, B. N., Knipe, D. M. & Howley, P. M. (Lippincott-Raven, Philadelphia), pp. 2447-2492. |
| 15. |
Rao, L. M., Debbas, M., Sabbatini, P., Hockenberry, D., Korsmeyer, S. & White, E.
(1992)
Proc. Natl. Acad. Sci. USA
89,
7742-7746
|
| 16. |
Shen, Y. & Shenk, T.
(1994)
Proc. Natl. Acad. Sci. USA
91,
8940-8944
|
| 17. |
Neil, S. D., Hemstrom, C., Virtanen, A. & Nevins, J. R.
(1990)
Proc. Natl. Acad. Sci. USA
87,
2008-2012
|
| 18. |
White, E. & Cipriani, R.
(1989)
Proc. Natl. Acad. Sci. USA
86,
9886-9890
|
| 19. | Tanaka, M. & Herr, W. (1990) Cell 60, 375-386 [CrossRef][ISI][Medline] . |
| 20. |
Morgenstern, J. P. & Land, H.
(1990)
Nucleic Acids Res.
18,
3587-3596
|
| 21. |
White, E. & Cipriani, R.
(1990)
Mol. Cell. Biol.
10,
120-130
|
| 22. |
Moore, M., Horikoshi, N. & Shenk, T.
(1996)
Proc. Natl. Acad. Sci. USA
93,
11295-11301
|
| 23. |
Wigler, M., Pellicer, A., Silverstein, S., Axel, R., Urlaub, G. & Chasin, L.
(1979)
Proc. Natl. Acad. Sci. USA
76,
1373-1376
|
| 24. |
Harlow, E., Franza, B. R. & Schley, C.
(1985)
J. Virol.
55,
533-546
|
| 25. | Bradley, W. E. & Letovanec, D. (1982) Somatic Cell Genet. 8, 51-66 [CrossRef][Medline] . |
| 26. |
Galloway, D. A., Nelson, J. A. & McDougall, J. K.
(1984)
Proc. Natl. Acad. Sci. USA
81,
4736-4740
|
| 27. | Galloway, D. A. & McDougall, J. K. (1983) Nature (London) 302, 21-24 [CrossRef][Medline] . |
| 28. | Nachtigal, M. & Nachtigal, S. (1978) Arch. Roum. Pathol. Exp. Microbiol. 37, 223-250 . |
| 29. | Luleci, G., Sakfzli, M. & Gunalp, A. (1980) Acta Virol. 24, 341-345 [Medline] . |
| 30. | AbuBaker, S., Au, W. W., Legator, M. S. & Albrecht, T. (1988) Environ. Mol. Mutagen. 12, 409-420 [Medline] . |
| 31. | Albrecht, T., Boldogh, I., Fons, M. P., Lee, C.H., AbuBaker, S., Russell, J. M. & Au, W. W. (1989) Subcell. Biochem. 15, 157-202 [Medline] . |
| 32. |
Debbas, M. & White, E.
(1993)
Genes Dev.
7,
546-554
|
| 33. |
White, E.
(1993)
Genes Dev.
7,
2277-2284
|
| 34. |
Nelson, J. A., Fleckenstein, B., Galloway, D. A. & McDougall, J. K.
(1982)
J. Virol.
43,
83-91
|
| 35. |
Nelson, J. A., Fleckenstein, B., Jahn, G., Galloway, D. A. & McDougall, J. K.
(1984)
J. Virol.
49,
109-115
|
| 36. |
El-Beik, T., Razzaque, A., Jariwalla, R., Cihlar, R. L. & Rosenthal, L. J.
(1986)
J. Virol.
60,
645-652
|
| 37. |
Jariwalla, R. J., Razzaque, A., Lawson, S. & Rosenthal, L. J.
(1989)
J. Virol.
63,
425-428
|
| 38. | Razzaque, A., Zhu, F. & Jones, C. (1991) Virology 181, 399-402 [CrossRef][Medline] . |
| 39. | Schlehofer, J. R. & zur Hausen, H. (1982) Virology 122, 471-475 [CrossRef][Medline] . |
| 40. |
Pilon, L., Royal, A. & Langelier, Y.
(1985)
J. Gen. Virol.
66,
259-265
|
| 41. |
Pilon, L., Langelier, Y. & Royal, A.
(1986)
Mol. Cell. Biol.
6,
2977-2983
|
| 42. |
Brandt, C. R., Buonaguro, F. M., McDougall, J. K. & Galloway, D. A.
(1987)
Nucleic Acids Res.
15,
561-573
|
| 43. | Hwang, C. B. C. & Shillitoe, E. J. (1990) Virology 178, 180-188 [CrossRef][Medline] . |
| 44. | Clarke, P. & Clements, J. B. (1991) Virology 182, 597-606 [CrossRef][Medline] . |
| 45. | Hwang, C. B. C. & Shillitoe, E. J. (1991) Virology 181, 620-629 [CrossRef][Medline] . |
| 46. | Kolodner, R. D. (1995) Trends Biochem. Sci. 20, 397-401 [CrossRef][ISI][Medline] . |
| 47. | Boldogh, I., Huang, E. S., Rady, P., Arany, I., Tyring, S. & Albrecht, T. (1994) Intervirology 37, 321-329 [Medline] . |
| 48. | Shenk, T. E. (1996) in Fields Virology, eds. Fields, B. N., Knipe, D. M. & Howley, P. M. (Lippincott-Raven, Philadelphia), pp. 2111-2148. |
| 49. | Jault, F. M., Jault, J. M., Ruchti, F., Fortunato, E. A., Clark, C., Corbeil, J., Richman, D. D. & Spector, D. H. (1995) J. Virol. 69, 6697-6704 [Abstract]. |
| 50. | Bresnahan, W. A., Boldogh, I., Thompson, E. A. & Albrecht, T. (1996) Virology 224, 150-160 [CrossRef][ISI][Medline] . |
| 51. | Lu, M. & Shenk, T. (1996) J. Virol. 70, 8850-8857 [Abstract]. |
| 52. | Dittmer, D. & Mocarski, E. S. (1997) J. Virol., in press. |
| 53. | Einhorn, L. & Ost, A. (1984) J. Infect. Dis. 149, 207-214 [ISI][Medline] . |
| 54. |
Rice, G. P. A., Schrier, R. D. & Oldstone, M. B. A.
(1984)
Proc. Natl. Acad. Sci. USA
81,
6134-6138
|
| 55. |
Albrecht, T., Nachtigal, M., St. Jeor, S. C. & Rapp, F.
(1976)
J. Gen. Virol.
30,
167-174
|
| 56. | Kamiya, S., Tanaka, J., Ogura, T., Ogura, H., Sato, H. & Hatano, M. (1986) Arch. Virol. 89, 131-144 [Medline] . |
This article has been cited by other articles in HighWire Press-hosted journals:
![]() |
C. Voisset, R. A. Weiss, and D. J. Griffiths Human RNA "Rumor" Viruses: the Search for Novel Human Retroviruses in Chronic Disease Microbiol. Mol. Biol. Rev., March 1, 2008; 72(1): 157 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. Luo, K. Rosenke, K. Czornak, and E. A. Fortunato Human Cytomegalovirus Disrupts both Ataxia Telangiectasia Mutated Protein (ATM)- and ATM-Rad3-Related Kinase-Mediated DNA Damage Responses during Lytic Infection J. Virol., February 15, 2007; 81(4): 1934 - 1950. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Shlapobersky, R. Sanders, C. Clark, and D. H. Spector Repression of HMGA2 Gene Expression by Human Cytomegalovirus Involves the IE2 86-Kilodalton Protein and Is Necessary for Efficient Viral Replication and Inhibition of Cyclin A Transcription. J. Virol., October 1, 2006; 80(20): 9951 - 9961. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Holtzman, J. T. Battaile, and A. C. Patel Immunogenetic Programs for Viral Induction of Mucous Cell Metaplasia Am. J. Respir. Cell Mol. Biol., July 1, 2006; 35(1): 29 - 39. [Full Text] [PDF] |
||||
![]() |
M. Gaspar and T. Shenk Human cytomegalovirus inhibits a DNA damage response by mislocalizing checkpoint proteins PNAS, February 21, 2006; 103(8): 2821 - 2826. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. L. Tarakanova, F. Suarez, S. A. Tibbetts, M. A. Jacoby, K. E. Weck, J. L. Hess, S. H. Speck, and H. W. Virgin IV Murine Gammaherpesvirus 68 Infection Is Associated with Lymphoproliferative Disease and Lymphoma in BALB {beta}2 Microglobulin-Deficient Mice J. Virol., December 1, 2005; 79(23): 14668 - 14679. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Castillo, F. M. Frame, H. A. Rogoff, M. T. Pickering, A. D. Yurochko, and T. F. Kowalik Human Cytomegalovirus IE1-72 Activates Ataxia Telangiectasia Mutated Kinase and a p53/p21-Mediated Growth Arrest Response J. Virol., September 1, 2005; 79(17): 11467 - 11475. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Holtzman, J. W. Tyner, E. Y. Kim, M. S. Lo, A. C. Patel, L. P. Shornick, E. Agapov, and Y. Zhang Acute and Chronic Airway Responses to Viral Infection: Implications for Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, August 1, 2005; 2(2): 132 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang and G. E. Sonenshein Induction of the RelB NF-{kappa}B Subunit by the Cytomegalovirus IE1 Protein Is Mediated via Jun Kinase and c-Jun/Fra-2 AP-1 Complexes J. Virol., January 1, 2005; 79(1): 95 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Reinhardt, G. B. Smith, C. T. Himmelheber, J. Azizkhan-Clifford, and E. S. Mocarski The Carboxyl-Terminal Region of Human Cytomegalovirus IE1491aa Contains an Acidic Domain That Plays a Regulatory Role and a Chromatin-Tethering Domain That Is Dispensable during Viral Replication J. Virol., January 1, 2005; 79(1): 225 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nevels, W. Brune, and T. Shenk SUMOylation of the Human Cytomegalovirus 72-Kilodalton IE1 Protein Facilitates Expression of the 86-Kilodalton IE2 Protein and Promotes Viral Replication J. Virol., July 15, 2004; 78(14): 7803 - 7812. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Burnett, S. Durrani, E. Stabile, M. Saji, C. W. Lee, T. D. Kinnaird, E. P. Hoffman, and S. E. Epstein Murine Cytomegalovirus Infection Increases Aortic Expression of Proatherosclerotic Genes Circulation, February 24, 2004; 109(7): 893 - 897. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Kalejta and T. Shenk The Human Cytomegalovirus UL82 Gene Product (pp71) Accelerates Progression through the G1 Phase of the Cell Cycle J. Virol., March 15, 2003; 77(6): 3451 - 3459. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. F. Kalejta, J. T. Bechtel, and T. Shenk Human Cytomegalovirus pp71 Stimulates Cell Cycle Progression by Inducing the Proteasome-Dependent Degradation of the Retinoblastoma Family of Tumor Suppressors Mol. Cell. Biol., March 15, 2003; 23(6): 1885 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wiebusch, J. Asmar, R. Uecker, and C. Hagemeier Human cytomegalovirus immediate-early over protein 2 (IE2)-mediated activation of cyclin E is cell-cycle-independent and forces S-phase entry in IE2-arrested cells J. Gen. Virol., January 1, 2003; 84(1): 51 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Cobbs, L. Harkins, M. Samanta, G. Y. Gillespie, S. Bharara, P. H. King, L. B. Nabors, C. G. Cobbs, and W. J. Britt Human Cytomegalovirus Infection and Expression in Human Malignant Glioma Cancer Res., June 1, 2002; 62(12): 3347 - 3350. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Fortunato, V. Sanchez, J. Y. Yen, and D. H. Spector Infection of Cells with Human Cytomegalovirus during S Phase Results in a Blockade to Immediate-Early Gene Expression That Can Be Overcome by Inhibition of the Proteasome J. Virol., May 3, 2002; 76(11): 5369 - 5379. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Heider, W. A. Bresnahan, and T. E. Shenk Construction of a rationally designed human cytomegalovirus variant encoding a temperature-sensitive immediate-early 2 protein PNAS, February 20, 2002; (2002) 52710599. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lanham, A. Herbert, A. Basarab, and P. Watt Detection of Cervical Infections in Colposcopy Clinic Patients J. Clin. Microbiol., August 1, 2001; 39(8): 2946 - 2950. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wienzek and M. Dobbelstein Viral and Cellular Factors That Target the Promyelocytic Leukemia Oncogenic Domains Strongly Activate a Glucocorticoid-Responsive Promoter J. Virol., June 1, 2001; 75(11): 5391 - 5397. [Abstract] [Full Text] |
||||
![]() |
M. Nevels, B. Täuber, T. Spruss, H. Wolf, and T. Dobner "Hit-and-Run" Transformation by Adenovirus Oncogenes J. Virol., April 1, 2001; 75(7): 3089 - 3094. [Abstract] [Full Text] |
||||
![]() |
E. Cesarman, E. A. Mesri, and M. C. Gershengorn Viral G Protein-coupled Receptor and Kaposi's Sarcoma: A Model of Paracrine Neoplasia? J. Exp. Med., February 7, 2000; 191(3): 417 - 422. [Full Text] [PDF] |
||||
![]() |
J. Doniger, S. Muralidhar, and L. J. Rosenthal Human Cytomegalovirus and Human Herpesvirus 6 Genes That Transform and Transactivate Clin. Microbiol. Rev., July 1, 1999; 12(3): 367 - 382. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cinat |